Pluristem Therapeutics Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Pluristem Therapeutics Inc. on October 30, 2017. The report details the pricing of a public offering of common stock on the Tel Aviv Stock Exchange and the engagement of an advisor for the transaction.
Key Financial Metrics
- Offering Size: 9,000,000 shares of common stock.
- Offering Price: NIS 5.90 per share (approximately $1.67 per share based on an exchange rate of US $1 to NIS 3.528).
- Expected Net Proceeds: Approximately $13,674,000 after deducting estimated offering expenses and advisor fees.
- Advisor Fees: Leader Underwriters (1993) Ltd. is to receive a 3% advisory fee, a 1% management fee, a potential 1% success fee, a 1% distribution fee, and a fixed NIS 30,000 fee for book running services.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity as it reports a specific capital event rather than periodic financial results.
Material Changes
The primary material change is the execution of a capital raise. The company priced the offering on October 30, 2017, with closing expected on or about October 31, 2017. This transaction is conducted pursuant to a shelf registration statement on Form S-3 declared effective on June 30, 2017.
Outlook, Risks, and Management Commentary
The company engaged Leader Underwriters (1993) Ltd. as an advisor on a "best efforts" basis; the advisor was not required to purchase or sell a specific number of shares. The filing includes standard disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. No specific operational guidance or risk factors beyond standard securities law disclaimers are detailed in this specific text.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected October 31, 2017) and the final number of shares sold.
- Confirm the final exchange rate used to convert NIS proceeds to USD, as the $13.674 million figure is an estimate based on an assumed rate.
- Review the attached Engagement Letter (Exhibit 10.1) for specific terms regarding the discretionary success fee.
- Check subsequent filings for the actual net proceeds received and any changes to the capital structure.